Moderna (NASDAQ:MRNA – Get Free Report) issued its earnings results on Thursday. The company reported ($3.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.59) by $0.52, Briefing.com reports. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 […]
Moderna (NASDAQ:MRNA – Get Free Report) had its price target upped by equities research analysts at Oppenheimer from $142.00 to $163.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price would suggest a potential upside of 30.50% from […]
Moderna (NASDAQ:MRNA – Get Free Report) had its price objective increased by equities researchers at Oppenheimer from $142.00 to $163.00 in a report released on Friday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s target price suggests a potential upside of 30.50% from the stock’s current price. MRNA has been […]
Value Star Asset Management Hong Kong Ltd purchased a new position in Moderna, Inc. (NASDAQ:MRNA – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 31,249 shares of the company’s stock, valued at approximately $3,107,000. Moderna makes up approximately 1.1% […]
Van ECK Associates Corp boosted its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 19.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 270,774 shares of the company’s stock after buying an additional 43,646 shares during the quarter. Van ECK Associates Corp’s […]